2,170 Shares in Inspire Medical Systems, Inc. (NYSE:INSP) Purchased by Wealthspire Advisors LLC

by · The Markets Daily

Wealthspire Advisors LLC bought a new position in shares of Inspire Medical Systems, Inc. (NYSE:INSP – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 2,170 shares of the company’s stock, valued at approximately $402,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Wasatch Advisors LP boosted its holdings in shares of Inspire Medical Systems by 1.6% in the 3rd quarter. Wasatch Advisors LP now owns 1,323,470 shares of the company’s stock worth $279,318,000 after purchasing an additional 20,481 shares in the last quarter. State Street Corp boosted its holdings in shares of Inspire Medical Systems by 78.0% in the 3rd quarter. State Street Corp now owns 1,049,784 shares of the company’s stock worth $221,557,000 after purchasing an additional 459,990 shares in the last quarter. Janus Henderson Group PLC boosted its holdings in shares of Inspire Medical Systems by 5.8% in the 3rd quarter. Janus Henderson Group PLC now owns 502,609 shares of the company’s stock worth $106,075,000 after purchasing an additional 27,374 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Inspire Medical Systems by 0.7% in the 3rd quarter. Geode Capital Management LLC now owns 483,654 shares of the company’s stock worth $102,102,000 after purchasing an additional 3,128 shares in the last quarter. Finally, TimesSquare Capital Management LLC purchased a new position in shares of Inspire Medical Systems in the 4th quarter worth about $80,419,000. 94.91% of the stock is currently owned by hedge funds and other institutional investors.

Inspire Medical Systems Stock Up 6.4 %

Inspire Medical Systems stock opened at $196.66 on Thursday. The company has a market capitalization of $5.83 billion, a P/E ratio of 113.68, a PEG ratio of 2.86 and a beta of 1.32. The stock’s 50 day moving average is $187.95 and its 200 day moving average is $193.23. Inspire Medical Systems, Inc. has a twelve month low of $123.00 and a twelve month high of $257.40.

Inspire Medical Systems (NYSE:INSP – Get Free Report) last posted its quarterly earnings results on Monday, February 10th. The company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.41. Inspire Medical Systems had a return on equity of 8.19% and a net margin of 6.67%. As a group, equities analysts expect that Inspire Medical Systems, Inc. will post 2.16 EPS for the current year.

Insider Buying and Selling

In other Inspire Medical Systems news, CTO John Rondoni sold 583 shares of the stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $170.49, for a total transaction of $99,395.67. Following the sale, the chief technology officer now directly owns 10,424 shares in the company, valued at approximately $1,777,187.76. This trade represents a 5.30 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Randy Ban sold 25,584 shares of the stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $183.50, for a total value of $4,694,664.00. Following the sale, the insider now owns 7,259 shares in the company, valued at approximately $1,332,026.50. This represents a 77.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 26,225 shares of company stock worth $4,806,530 in the last 90 days. Insiders own 4.10% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on INSP shares. Robert W. Baird cut their price objective on Inspire Medical Systems from $252.00 to $248.00 and set an “outperform” rating for the company in a report on Tuesday, February 11th. Stifel Nicolaus lowered their target price on Inspire Medical Systems from $200.00 to $190.00 and set a “hold” rating for the company in a research note on Tuesday, January 21st. Royal Bank of Canada reaffirmed an “outperform” rating and set a $260.00 price target on shares of Inspire Medical Systems in a research report on Tuesday, February 11th. Truist Financial lowered their price target on Inspire Medical Systems from $250.00 to $235.00 and set a “buy” rating for the company in a research report on Tuesday, February 11th. Finally, Morgan Stanley lowered their price target on Inspire Medical Systems from $230.00 to $220.00 and set an “overweight” rating for the company in a research report on Tuesday, February 11th. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $228.82.

Read Our Latest Research Report on INSP

Inspire Medical Systems Profile

(Free Report)

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.

Featured Articles

Want to see what other hedge funds are holding INSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inspire Medical Systems, Inc. (NYSE:INSP – Free Report).